Last reviewed · How we verify
NCT01858987: CRUNSHII
Stapler vs. LigaSure in Elective Hepatic Resection
NA trial testing Stapler hepatectomy in Liver Resection in 138 participants. Completed in 14 August 2014.
17 July 2014
Quick facts
| Lead sponsor | Heidelberg University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 138 |
| Start date | 2 November 2011 |
| Primary completion | 17 July 2014 |
| Estimated completion | 14 August 2014 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Stapler hepatectomy
- LigaSure hepatectomy
- Ligasure
- vascular staple
Conditions studied
- Liver Resection — all drugs for Liver Resection →
Sponsor
Heidelberg University
Who can join
18 and older, any sex, with Liver Resection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The optimal technique of parenchymal transection in liver surgery has remained a matter of controversial debate among hepatobiliary surgeons. The optimal technique should enable secure sealing of the vascular and biliary structures that results in low intraoperative blood loss as well as low postoperative complication rates. Although numerous devices have been introduced and are used widely, high-level evidence, randomized controlled trials, that evaluate efficacy and safety of these devices are scarce. In the present randomized controlled trial two techniques of hepatic resection using vascular staplers and the LigaSure vessel sealing device are compared. While the primary endpoint is intraoperative blood loss a set of general and surgical variables will be analyzed to evaluate efficacy and safety of both methods.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Randomized clinical trial of stapler hepatectomy versus LigaSure™ transection in elective hepatic resection.
Fritzmann J, Kirchberg J, Sturm D, Ulrich AB, et al · · 2018 · cited 17× · PMID 30069876 · DOI 10.1002/bjs.10902 -
Infrahepatic Inferior Vena Cava Clamping does not Increase the Risk of Pulmonary Embolism Following Hepatic Resection.
Birgin E, Mehrabi A, Sturm D, Reißfelder C, et al · · 2021 · cited 7× · PMID 34047820 · DOI 10.1007/s00268-021-06159-4
Verify or expand the search:
- PubMed search for NCT01858987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Resection
Currently open trials in the same condition.
- NCT06638502 — Safety of HRX215 in Patients After Minor and Major Liver Resection · Phase 1, PHASE2 · recruiting
- NCT07385521 — The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases · recruiting
- NCT06905015 — Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver · NA · recruiting
Other Heidelberg University trials
Trials by the same sponsor.
- NCT07106294 — Hyperspectral Imaging for Prediction of Preeclampsia · recruiting
- NCT06651164 — Psychosomatic Risk Screening · NA · completed
- NCT07378345 — Optimization of Communication Between Surgery and Pathology · NA · completed
- NCT06018272 — Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany · NA · recruiting
- NCT06852599 — Long-term Outcomes of Implants in Patients with Periodontitis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01858987 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heidelberg University
- Last refreshed: 9 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01858987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing